News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
679,105 Results
Type
Article (38784)
Company Profile (247)
Press Release (640074)
Section
Business (203535)
Career Advice (1977)
Deals (35344)
Drug Delivery (78)
Drug Development (80618)
Employer Resources (167)
FDA (16017)
Job Trends (14778)
News (343726)
Policy (32406)
Tag
Academia (2528)
Africa (711)
Alliances (48975)
Alzheimer's disease (1147)
Approvals (15939)
Arizona (174)
Artificial intelligence (69)
Asia (36804)
Australia (5984)
Bankruptcy (350)
Best Places to Work (11282)
Biosimilars (63)
Biotechnology (176)
C2C Services and Suppliers (78790)
California (1886)
Canada (937)
Cancer (491)
Career advice (1647)
Cell therapy (121)
China (150)
Clinical research (63225)
Collaboration (139)
Colorado (79)
Compensation (81)
Connecticut (75)
COVID-19 (2487)
Cystic fibrosis (73)
Data (314)
Diabetes (81)
Diagnostics (5972)
Drug pricing (63)
Earnings (83652)
Employer resources (142)
Europe (78626)
Events (107820)
Executive appointments (153)
FDA (16244)
Florida (265)
Funding (149)
Gene therapy (92)
GLP-1 (510)
Government (4290)
Healthcare (18613)
Hotbed/Location (480946)
Illinois (255)
Indiana (147)
Infectious disease (2516)
Inflammatory bowel disease (91)
Interviews (305)
IPO (16202)
Job creations (3618)
Job search strategy (1412)
Kansas (94)
Layoffs (393)
Legal (7830)
Lung cancer (110)
Manufacturing (86)
Maryland (398)
Massachusetts (1528)
Medical device (13046)
Medtech (13051)
Mergers & acquisitions (19014)
Metabolic disorders (247)
Michigan (124)
Minnesota (214)
Neuroscience (1293)
New Jersey (579)
New York (596)
NextGen Class of 2024 (6479)
Non-profit (4457)
North Carolina (588)
Northern California (825)
Obesity (146)
Ohio (104)
Opinion (171)
Patents (74)
Pennsylvania (582)
People (55842)
Pharmaceutical (60)
Phase I (19588)
Phase II (27845)
Phase III (20806)
Pipeline (112)
Postmarket research (2546)
Preclinical (8317)
Press Release (64)
Rare diseases (130)
Real estate (5882)
Recruiting (63)
Regulatory (21198)
Research institute (2304)
Resumes & cover letters (346)
South America (1085)
Southern California (767)
Startups (3559)
Texas (240)
United States (8575)
Vaccines (473)
Washington State (253)
Weight loss (127)
Date
Today (103)
Last 7 days (619)
Last 30 days (2446)
Last 365 days (37125)
2024 (26206)
2023 (40074)
2022 (51173)
2021 (55713)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32111)
2016 (31480)
2015 (37553)
2014 (31318)
2013 (26346)
2012 (28570)
2011 (29263)
2010 (27328)
679,105 Results for "skinvisible inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Skinvisible Expands Obesity Patent Application for Transdermal Delivery
Skinvisible Pharmaceuticals, Inc. (OTCQB:SKVI), an innovative topical / transdermal pharmaceutical research and development company, today announced the filing of a second patent application for its groundbreaking Invisicare® technology and its transdermal delivery of obesity and glucose-controlling agents.
June 24, 2024
·
5 min read
BioMidwest
Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal Treatment
Skinvisible Pharmaceuticals, Inc., an innovative pharmaceutical research and development company, announced a major advancement in the battle against obesity.
May 29, 2024
·
4 min read
Skinvisible Announces Significant Progress in Licensee’s Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome
Skinvisible, Inc. (“Skinvisible”) (OTCQB:SKVI) is excited to share a promising update on the ongoing clinical trials conducted by its licensee, Quoin Pharmaceuticals, Inc. (“Quoin”) (NASDAQ:QNRX).
February 14, 2024
·
4 min read
Press Releases
Promising Data on Transdermal Obesity Formulations Announced by Skinvisible
July 12, 2024
·
4 min read
Policy
Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New Drug
Skinvisible, Inc., is pleased to announce that its licensee Quoin Pharmaceuticals, Inc., has received U.S. FDA acceptance of its Investigational New Drug application for its licensed formulation which uses Skinvisible’s Invisicare® proprietary drug delivery technology.
June 6, 2022
·
3 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).
July 1, 2024
·
5 min read
Lophos Holdings Inc. Announces the Completion of Securities Purchase Agreement with ThreeD Capital Inc.
Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company”), a Canadian bioscience company focused on the cultivation and sale of Lophophora williamsii (“Peyote”) and ThreeD Capital Inc. (CSE: IDK) (OTCQB: IDKFF) (“ThreeD”), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, are pleased to announce the completion of its previously announced Securities Purchase Agreement (the “Agreement”).
June 20, 2024
·
4 min read
Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials
Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”).
June 28, 2024
·
4 min read
Merit Medical Announces Asset Purchase Agreement with EndoGastric Solutions, Inc.®
Merit Medical Systems, Inc., a global leader of healthcare technology, announced it has executed an asset purchase agreement with EndoGastric Solutions, Inc. for a total cash consideration of approximately $105 million.
July 1, 2024
·
18 min read
1 of 67,911
Next